Overall, this study built a rational for targeting CK2α for CLL therapy by reporting i) an association between the expression of CSNK2A1 with short TTFT and short OS, ii) a correlation the expression of genes implicated in CLL survival and proliferation-dependent pathways with the expression of CSNK2A in CLL cells, iii) identification of CK2α interaction patterns that associate with the aggressiveness of CLL. The gene discussed is CSNK2A1; the disease is B-cell chronic lymphocytic leukemia.